

CAPZA2 Antibody (Center) Blocking Peptide

Synthetic peptide Catalog # BP2895c

Specification

CAPZA2 Antibody (Center) Blocking Peptide - Product Information

Primary Accession

P47755

CAPZA2 Antibody (Center) Blocking Peptide - Additional Information

Gene ID 830

Other Names

F-actin-capping protein subunit alpha-2, CapZ alpha-2, CAPZA2

Target/Specificity

The synthetic peptide sequence used to generate the antibody AP2895c was selected from the Center region of human CAPZA2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

CAPZA2 Antibody (Center) Blocking Peptide - Protein Information

Name CAPZA2

Function

F-actin-capping proteins bind in a Ca(2+)-independent manner to the fast growing ends of actin filaments (barbed end) thereby blocking the exchange of subunits at these ends. Unlike other capping proteins (such as gelsolin and severin), these proteins do not sever actin filaments.

CAPZA2 Antibody (Center) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

• Blocking Peptides

CAPZA2 Antibody (Center) Blocking Peptide - Images



CAPZA2 Antibody (Center) Blocking Peptide - Background

CAPZA2 is a member of the F-actin capping protein alpha subunit family. It is the alpha subunit of the barbed-end actin binding protein Cap Z. By capping the barbed end of actin filaments, Cap Z regulates the growth of the actin filaments at the barbed end.

CAPZA2 Antibody (Center) Blocking Peptide - References

Denoeud, F., et.al., Genome Res. 17 (6), 746-759 (2007) Miyagawa, Y., et.al., Mol. Hum. Reprod. 8 (6), 531-539 (2002)